Pembrolizumab Approved in Europe for Urothelial Carcinoma
September 6th 2017The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.
Read More
Immunotherapy Gains Frontline Foothold in NSCLC
May 29th 2017Less than 2 years after checkpoint blockade immunotherapy first became available for patients with non-small cell lung cancer, the PD-1 inhibitor pembrolizumab is poised to reshape the treatment paradigm for previously untreated individuals without molecular mutations.
Read More